• Je něco špatně v tomto záznamu ?

Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy

R. Nabi, Z. Moldoveanu, Q. Wei, ET. Golub, HG. Durkin, RM. Greenblatt, BC. Herold, MJ. Nowicki, S. Kassaye, MW. Cho, A. Pinter, AL. Landay, J. Mestecky, PA. Kozlowski,

. 2017 ; 12 (7) : e0180245. [pub] 20170703

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016506

Mechanisms responsible for natural control of human immunodeficiency type 1 (HIV) replication in elite controllers (EC) remain incompletely defined. To determine if EC generate high quality HIV-specific IgA responses, we used Western blotting to compare the specificities and frequencies of IgA to HIV antigens in serum of gender-, age- and race-matched EC and aviremic controllers (HC) and viremic noncontrollers (HN) on highly active antiretroviral therapy (HAART). Concentrations and avidity of IgA to HIV antigens were measured using ELISA or multiplex assays. Measurements for IgG were performed in parallel. EC were found to have stronger p24- and V1V2-specific IgG responses than HN, but there were no IgG differences for EC and HC. In contrast, IgA in EC serum bound more frequently to gp160 and gag proteins than IgA in HC or HN. The avidity of anti-gp41 IgA was also greater in EC, and these subjects had stronger IgA responses to the gp41 heptad repeat region 1 (HR1), a reported target of anti-bacterial RNA polymerase antibodies that cross react with gp41. However, EC did not demonstrate greater IgA responses to E. coli RNA polymerase or to peptides containing the shared LRAI sequence, suggesting that most of their HR1-specific IgA antibodies were not induced by intestinal microbiota. In both EC and HAART recipients, the concentrations of HIV-specific IgG were greater than HIV-specific IgA, but their avidities were comparable, implying that they could compete for antigen. Exceptions were C1 peptides and V1V2 loops. IgG and IgA responses to these antigens were discordant, with IgG reacting to V1V2, and IgA reacting to C1, especially in EC. Interestingly, EC with IgG hypergammaglobulinemia had greater HIV-specific IgA and IgG responses than EC with normal total IgG levels. Heterogeneity in EC antibody responses may therefore be due to a more focused HIV-specific B cell response in some of these individuals. Overall, these data suggest that development of HIV-specific IgA responses and affinity maturation of anti-gp41 IgA antibodies occurs to a greater extent in EC than in subjects on HAART. Future studies will be required to determine if IgA antibodies in EC may contribute in control of viral replication.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016506
003      
CZ-PrNML
005      
20180515103733.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0180245 $2 doi
035    __
$a (PubMed)28671952
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nabi, Rafiq $u Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, United States of America.
245    10
$a Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy / $c R. Nabi, Z. Moldoveanu, Q. Wei, ET. Golub, HG. Durkin, RM. Greenblatt, BC. Herold, MJ. Nowicki, S. Kassaye, MW. Cho, A. Pinter, AL. Landay, J. Mestecky, PA. Kozlowski,
520    9_
$a Mechanisms responsible for natural control of human immunodeficiency type 1 (HIV) replication in elite controllers (EC) remain incompletely defined. To determine if EC generate high quality HIV-specific IgA responses, we used Western blotting to compare the specificities and frequencies of IgA to HIV antigens in serum of gender-, age- and race-matched EC and aviremic controllers (HC) and viremic noncontrollers (HN) on highly active antiretroviral therapy (HAART). Concentrations and avidity of IgA to HIV antigens were measured using ELISA or multiplex assays. Measurements for IgG were performed in parallel. EC were found to have stronger p24- and V1V2-specific IgG responses than HN, but there were no IgG differences for EC and HC. In contrast, IgA in EC serum bound more frequently to gp160 and gag proteins than IgA in HC or HN. The avidity of anti-gp41 IgA was also greater in EC, and these subjects had stronger IgA responses to the gp41 heptad repeat region 1 (HR1), a reported target of anti-bacterial RNA polymerase antibodies that cross react with gp41. However, EC did not demonstrate greater IgA responses to E. coli RNA polymerase or to peptides containing the shared LRAI sequence, suggesting that most of their HR1-specific IgA antibodies were not induced by intestinal microbiota. In both EC and HAART recipients, the concentrations of HIV-specific IgG were greater than HIV-specific IgA, but their avidities were comparable, implying that they could compete for antigen. Exceptions were C1 peptides and V1V2 loops. IgG and IgA responses to these antigens were discordant, with IgG reacting to V1V2, and IgA reacting to C1, especially in EC. Interestingly, EC with IgG hypergammaglobulinemia had greater HIV-specific IgA and IgG responses than EC with normal total IgG levels. Heterogeneity in EC antibody responses may therefore be due to a more focused HIV-specific B cell response in some of these individuals. Overall, these data suggest that development of HIV-specific IgA responses and affinity maturation of anti-gp41 IgA antibodies occurs to a greater extent in EC than in subjects on HAART. Future studies will be required to determine if IgA antibodies in EC may contribute in control of viral replication.
650    _2
$a dospělí $7 D000328
650    _2
$a afinita protilátek $7 D000915
650    12
$a vysoce aktivní antiretrovirová terapie $7 D023241
650    _2
$a ELISA $7 D004797
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a HIV protilátky $x biosyntéza $7 D015483
650    _2
$a HIV obalový protein gp41 $x imunologie $7 D015700
650    _2
$a HIV infekce $x farmakoterapie $x imunologie $7 D015658
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin A $x krev $7 D007070
650    _2
$a imunoglobulin G $x krev $7 D007074
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Moldoveanu, Zina $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States of America.
700    1_
$a Wei, Qing $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States of America.
700    1_
$a Golub, Elizabeth T $u Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
700    1_
$a Durkin, Helen G $u Departments of Pathology and Medicine, SUNY Downstate, Brooklyn, NY, United States of America.
700    1_
$a Greenblatt, Ruth M $u Departments of Medicine and Epidemiology/Biostastistics, University of California, San Francisco, CA, United States of America.
700    1_
$a Herold, Betsy C $u Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine, Bronx, NY, United States of America.
700    1_
$a Nowicki, Marek J $u Department of Pediatrics, University of Southern California, Los Angeles, CA, United States of America.
700    1_
$a Kassaye, Seble $u Department of Medicine, Georgetown University, Washington, D.C., United States of America.
700    1_
$a Cho, Michael W $u Department of Biomedical Sciences, Iowa State University, Ames, IA, United States of America.
700    1_
$a Pinter, Abraham $u Public Health Research Institute, Rutgers New Jersey Medical School, Newark, NJ, United States of America.
700    1_
$a Landay, Alan L $u Department of Immunity and Emerging Pathogens, Rush University Medical Center, Chicago, IL, United States of America.
700    1_
$a Mestecky, Jiri $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States of America. Institute of immunology and Microbiology 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Kozlowski, Pamela A $u Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, United States of America.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 12, č. 7 (2017), s. e0180245
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28671952 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103907 $b ABA008
999    __
$a ok $b bmc $g 1300130 $s 1013346
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 12 $c 7 $d e0180245 $e 20170703 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20180515
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace